TABLE 1

Patients with Primary Prostate Cancer

Patient no.*	Age (y)	PSA (ng/mL)	Positive biopsy	Histology	Clinical stage	SUV in most radioactive area
						¹⁸F-FECh		¹¹C-Choline
						30 min	60 min	5 min	20 min
1	67	4.6	1/6	Mod. diff.	B1	2.84	3.25	3.43	4.75
2	71	5.5	3/6	Well-diff.	B1	1.97	1.86	1.66	1.86
3	75	6.6	3/6	Well-diff.	B1	2.78	2.83	2.85	2.75
4	63	7.7	2/6	Well-diff.	B1	2.50	2.90	2.48	2.48
5	62	8.4	4/6	Mod. diff.	B2	4.08	4.25	4.37	4.07
6	70	19.5	3/7	Well-diff.	B1	5.39	5.14	4.79	5.43
7	78	19.6	3/7	Mod. diff.	D2	4.25	4.36	3.10	4.90
8	77	36.0	7/7	Poor diff.	D1	3.12	3.27	3.93	4.67
9	75	41.8	3/6	Poor diff.	B1	2.71	3.30	3.28	3.28
10	68	45.7	5/6	Poor diff.	D2	3.63	3.97	4.71	5.21
11	72	45.9	3/6	Mod. diff.	B1	3.43	2.55	4.56	4.51
12	72	51.3	6/6	Poor diff.	D2	5.51	6.46	7.22	7.58
13	64	80.0	6/6	Mod. diff.	C	3.42	3.35	3.88	4.08
14	78	104.0	5/6	Poor diff.	D2	4.41	4.66	3.17	3.57
15	68	126.3	6/6	Mod. diff.	D2	4.88	4.70	4.94	5.77
16	82	242.6	4/4	Mod. diff.	D2	6.47	7.50	6.04	7.11

↵* Patient 5 underwent total prostatectomy and all other patients received hormonal therapy after PET study.
Mod. = moderately; diff. = differentiated; poor = poorly.